BioCentury
ARTICLE | Company News

GammaDelta spins out Adaptate to focus on antibody therapies

October 16, 2019 7:02 AM UTC
Updated on Oct 16, 2019 at 4:30 PM UTC

As GammaDelta nears bringing its T cell therapies to the clinic, it’s spinning out Adaptate to focus on the development of its γδ antibody-based programs.

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) has a time-limited option to acquire Adaptate Biotherapeutics Ltd. and has provided undisclosed funding, along with Abingworth. ...